Dora wrote:
> Are you saying, then, that all the unpleasant things that Henry is
> experiencing are not necessarily from the metastisized cancer, but are from
> the Lupron? This was certainly not explained to him by the uro.
Anyone can access the FDA's website and look up drugs. Here
is one posting (of many) re: LUPRON
[ long, even with chemisty and other notions removed ]
LUPRON (leuprolide acetate injection)
DESCRIPTION This is the cached copy of
http://www.fda.gov/medwatch/SAFETY/2.../Lupron_PI.pdf
Page 1
LUPRON (leuprolide acetate injection)
DESCRIPTION Leuprolide acetate is a synthetic nonapeptide analog of
naturally occurring gonadotropin releasing hormone (GnRH or LH-RH).
The analog possesses greater potency than the natural hormone.
CLINICAL PHARMACOLOGY: Leuprolide acetate, an LH-RH agonist, acts as a
potent inhibitor of gonadotropin secretion when given continuously and
in therapeutic doses. Animal and human studies indicate that following
an initial stimulation of gonadotropins, chronic administration
of leuprolide acetate results in suppression of ovarian and testicular
steroidogenesis.
In males, testosterone is reduced to castrate levels.
Page 2
Page 3
WARNINGS Initially, LUPRON, like other LH-RH agonists, causes increases
in serum levels of testosterone. Transient worsening of symptoms, or
the occurrence of additional signs and symptoms of prostate cancer, may
occasionally develop during the first few weeks of LUPRON treatment.
A number of patients may experience an increase in bone pain, which can
be managed symptomatically. As with other LH-RH agonists, isolated
cases
of ureteral obstruction and spinal cord compression have been observed,
which may contribute to paralysis with or without fatal complications.
Page 4
ADVERSE REACTIONS: In the majority of patients testosterone levels
increased above baseline during the first week, declining thereafter
to baseline levels or below by the end of the second week of treatment.
This transient increase was occasionally associated with a temporary
worsening of signs and symptoms, usually manifested by an increase in
bone pain (see WARNINGS section). In a few cases a temporary worsening
of existing hematuria and urinary tract obstruction occurred during the
first week. Temporary weakness and paresthesia of the lower limbs have
been reported in a few cases. Potential exacerbations of signs and
symptoms during the first few weeks of treatment is a concern in
patients with vertebral metastases and/or urinary obstruction which,
if aggravated, may lead to neurological problems or increase the
obstruction. In a comparative trial of LUPRON (leuprolide acetate)
Injection versus DES, in 5% or more of the patients receiving either
drug, the following adverse reactions were reported to have a possible
or probable relationship to drug as ascribed by the treating physician.
Often, causality is difficult to assess in patients with metastatic
prostate cancer. Reactions considered not drug related are excluded.
Page 5
LUPRON DES (N=98)
(N=101)
Number of Reports
Cardiovascular System
Congestive heart
failure.................1......................... ......5
ECG changes/ischemia................19........................ .....22
High blood
pressure......................8................... .............5
Murmur..........................................3. ...............................8
Peripheral
edema........................12................... ...........30
Phlebitis/thrombosis......................2................. .............10
Gastrointestinal System
Anorexia.........................6............5
Constipation.....................7............9
Nausea/vomiting..................5...........17
Endocrine System
*Decreased testicular size.......7...........11
*Gynecomastia/breast tenderness or pain.7....63
*Hot flashes....................55...........12
*Impotence.......................4...........12
Hemic and Lymphatic System
Anemia...........................5............5
Musculoskeletal System
Bone pain........................5............2
Myalgia..........................3............9
Central/Peripheral Nervous System
Dizziness/lightheadedness........5............7
General pain....................13...........13
Headache.........................7............4
Insomnia/sleep disorders.........7............5
Respiratory System
Dyspnea..........................2............8
Sinus congestion.................5............6
Integumentary System
Dermatitis.......................5............8
Urogenital System
Frequency/urgency................6............8
Hematuria........................6............4
Urinary tract infection..........3............7
Miscellaneous
Asthenia........................10...........10
*Physiologic effect of decreased testosterone.
In this same study, the following adverse reactions were reported
in less than 5% of the patients on LUPRON.
Cardiovascular System: Angina, Cardiac arrhythmias,
Myocardial infarction, Pulmonary emboli;
Gastrointestinal System: Diarrhea, Dysphagia, Gastrointestinal
bleeding,
Gastrointestinal disturbance, Peptic ulcer, Rectal polyps;
Endocrine System: Libido decrease,
Thyroid enlargement;
Musculoskeletal System: Joint pain;
Central/Peripheral Nervous System: Anxiety, Blurred vision,
Lethargy, Memory disorder, Mood swings, Nervousness, Numbness,
Paresthesia, Peripheral neuropathy, Syncope/ blackouts, Taste
disorders;
Respiratory System: Cough, Pleural rub, Pneumonia, Pulmonary
fibrosis;
Integumentary System: Carcinoma of skin/ear, Dry skin, Ecchymosis,
Hair loss, Itching, Local skin reactions, Pigmentation, Skin lesions;
Urogenital System: Bladder spasms, Dysuria, Incontinence,
Testicular pain, Urinary obstruction;
Miscellaneous: Depression, Diabetes, Fatigue, Fever/chills,
Hypoglycemia, Increased BUN, Increased calcium, Increased
creatinine, Infection/inflammation, Ophthalmologic disorders,
Swelling (temporal bone).
The following additional adverse reactions have been reported with
LUPRON or LUPRON DEPOT (leuprolide acetate for depot suspension)
during other clinical trials and/or during postmarketing surveillance.
Reactions considered as nondrug related by the treating physician are
excluded.
Cardiovascular System: Hypotension, Transient ischemic attack/stroke;
Gastrointestinal System: Hepatic dysfunction;
Endocrine System: Libido increase;
Hemic and Lymphatic System: Decreased WBC, Hemoptysis;
Musculoskeletal System: Ankylosing spondylosis, Pelvic fibrosis;
Central/Peripheral Nervous System: Hearing disorder, Peripheral
neuropathy, Spinal fracture/paralysis;
Respiratory System: Pulmonary infiltrate, Respiratory disorders;
Integumentary System: Hair growth;
Urogenital System: Penile swelling, Prostate pain;
Miscellaneous: Hypoproteinemia, Hard nodule in throat,
Weight gain, Increased uric acid.
Changes in Bone Density: Decreased bone density has been reported
in the medical literature in men who have had orchiectomy or who
have been treated with an LH-RH agonist analog. In a clinical trial,
25 men with prostate cancer, 12 of whom had been treated previously
with leuprolide acetate for at least six months, underwent bone
density studies as a result of pain. The leuprolide-treated group
had lower bone density scores than the nontreated control group.
It can be anticipated that long periods of medical castration in
men will have effects on bone density.
Page 7
INFORMATION FOR PATIENTS Be sure to consult your physician with any
questions you may have or for information about LUPRON (leuprolide
acetate injection) and its use. What is LUPRON? LUPRON (leuprolide
acetate injection) is chemically similar to gonadotropin releasing
hormone (GnRH or LH-RH) a hormone which occurs naturally in your body.
Normally, your body releases small amounts of LH-RH and this leads
to events which stimulate the production of sex hormones. However,
when you inject LUPRON (leuprolide acetate) Injection, the normal
events that lead to sex hormone production are interrupted and
testosterone is no longer produced by the testes. LUPRON must be
injected because, like
insulin which is injected by diabetics,
LUPRON is inactive when taken by mouth. If you were to discontinue
the drug for any reason, your body would begin making testosterone
again.
Page 8
SOME SPECIAL ADVICE
You may experience hot flashes when using LUPRON (leuprolide acetate)
Injection. During the first few weeks of treatment you may experience
increased bone pain, increased difficultyin urinating, and less
commonly
but most importantly, you may experience the onset or aggravation of
nerve symptoms. In any of these events, discuss the symptoms with your
doctor. Like other treatment options, LUPRON may cause impotence.
Notify
your doctor if you develop new or worsened symptoms after beginning
LUPRON treatment.